Citations

Clear

1279 citation(s) found for "Taylor, A".

Multicentre randomised comparative effectiveness trial of cleavage-stage versus blastocyst-stage embryo transfer in patients with few embryos (PRECISE): implementation of a study protocol in reproductive medicine
Neuhausser, Werner , Vaughan, Denis A. , Sakkas, Denny, Anchan, Raymond M. , Hornstein, Mark D., Reeder, Harrison T, Barnhart, Kurt T, Cedars, Marcelle I. , Halıcıgil, Cihan , Beck, Michelle, Marsh, Erica E. , Gracia, Clarisa R. , Rosenwaks, Zev, Rabideau, Dustin J. , Trial, Stakeholder Advisory Group and Study Investigators of the PRECISE, Trial, Data and Safety Monitoring Board and Study Investigators of the PRECISE, Neuhausser, Werner M , Sakkas, Denny , Penzias, Alan S. , Reeder, Harrison Thomas , Barnhart, Kurt T. , Stewart, Elizabeth A. , Taylor, Hugh S. , Hacker, Michele R. , Rosenwaks, Zev, Williams, Zev

Mayo Clinic

BMJ Open | August 4, 2026 | Volume: 16 | Issue: 8 | Pages: e107903

10.1136/bmjopen-2025-107903 | PMID 42552004 Get It

Background With improvements in in vitro culture techniques, there has been a steady shift in practice to transfer in vitro fertilisation (IVF) embryos at the blastocyst-stage to increase pregnancy rates per embryo transfer (ET) and reduce the risk of multiple pregnancy. In patients with fewer embryos (≤5 zygotes), fresh cleavage-stage ET is still commonly performed to reduce the risk of cycle cancellation if no embryo survives to the blastocyst-stage in vitro. However, evidence for improved outcomes with cleavage-stage embryo transfer in this subgroup of patients is lacking. We will compare blastocyst-stage to cleavage-stage ET with regard to cumulative live birth rates (CLBR) per oocyte retrieval and other patient-centred cycle outcomes in patients with ≤5 zygotes. Methods and analysis Multicentre, randomised pragmatic comparative effectiveness trial with superiority design comparing blastocyst-stage to cleavage-stage ET in patients with ≤5 zygotes. This trial will enrol and randomise 1126 women aged 18–44 undergoing IVF to either fresh cleavage-stage or blastocyst-stage ET at eleven IVF centres. Surplus embryos will be vitrified at the blastocyst-stage. The primary outcome is the CLBR per oocyte retrieval. Secondary outcomes include: multiple pregnancy, pregnancy loss <20 weeks and cycle cancellation. Exploratory outcomes include: live birth per fresh ET, ectopic pregnancy, time to pregnancy, stillbirth, preterm birth, financial burden, patient distress and facilitators and barriers for patient involvement and implementation. All primary analyses will be conducted according to the intent-to-treat principle. We also will report per-protocol analyses as a sensitivity analysis. A multidisciplinary stakeholder team, including a 5-patient stakeholder panel, will participate in study design, conduct and oversight. Ethics and dissemination The Institutional Review Board at Beth Israel Deaconess Medical Center (BIDMC) provides central regulatory oversight. Results will inform timing of embryo transfer in patients with ≤5 zygotes and will be disseminated through academic publications, meeting presentations and communications to advocacy groups and patient participants. Trial registration number NCT06746129 .
CoCoRV-nf: a powerful and cost-effective tool for rare variant analysis leveraging external biobank sequence data identified new candidate predisposition genes in amyotrophic lateral sclerosis and neuroblastoma
Tithi, Saima Sultana , Cooper-Knock, Johnathan, Benatar, Michael , Wuu, Joanne, Taylor, J Paul, Wu, Gang , Chen, Wenan , Cooper‐Knock, Johnathan , Wu, Gang , Wuu, Joanne , Taylor, J Paul

Mayo Clinic

Human Molecular Genetics | August 4, 2026 | Volume: 35 | Issue: 17 | Pages: No page available

10.1093/hmg/ddag076 | PMID 42574250 Get It

Abstract Although sequencing costs have steadily decreased with advances in technology, they remain high for large scale studies. The design of traditional individual-disease sequencing studies is either case only or cases with relatively few controls, resulting in potential loss of statistical power for discovery of disease associated genes. Here we show that for a given number of sequenced cases, a large control sample size is critical to maximize power for rare variant burden analysis. Furthermore, we have developed an end-to-end workflow based tool (CoCoRV-nf) to facilitate the use of external biobank sequence resources as controls. The modules include consistent variant QC, variant annotation, ancestry population prediction, and gene based burden analysis using summary genotype information, and combined analysis from multiple independent results. The tool supports exomes and genomes from gnomAD and All of Us as controls with preprocessed datasets. We apply the tool in two rare neurological diseases: amyotrophic lateral sclerosis and neuroblastoma. For each disease, two case cohorts are paired with gnomAD and All of Us data, respectively, followed by a combined analysis. Not only did we recapture known genes, but also, we identified new candidate genes for both diseases. By leveraging multiple large external biobank sequence data, we demonstrate the feasibility of using our tool to maximize statistical power to identify new disease predisposition genes.
Effect of time to palliative epilepsy surgery on outcomes
Crutcher, Robert M. , Horvat, David , Caraway, Avery R. , Arredondo, Kristen H. , Abel, Taylor J. , Agarwal, Nitin , Alexander, Allyson , Armstrong, Dallas , Auguste, Kurtis I. , Bernardo, Danilo , Bolton, Jeffrey , Bonda, David , Depositario‐Cabacar, Dewi F. , Groves, Aran, Hauptman, Jason S. , Knox, Andrew , Lin, Jenny, McGoldrick, Patricia E. , Miller, D. , Ostendorf, Adam P. , Pichon, Pilar, Reddy, Shilpa B. , Samanta, Debopam , Singh, Rani K. , Wagner, Janelle L. , Galán, Fernando , Perry, Μ. Scott , Ciliberto, Michael A. , Horvat, David E , Alexander, Allyson L , Armstrong, Dallas Michael , Depositario Cabacar, Dewi Frances , Eschbach, Krista , Gaillard, William D , Hauptman, Jason , Javarayee, Pradeep K , Karakas, Cemal , Knox, Andrew T , McGoldrick, Patricia E , Miller, Derryl J , Novotny, Edward J , Ostendorf, Adam P , Pichon, Pilar D , Reddy, Shilpa B , Samanta, Debopam , Singh, Rani K , Wagner, Janelle , Wolf, Steven , Wong-Kisiel, Lily C. , Galan, Fernando N , Perry, Michael Scott , Ciliberto, Michael A , Auguste, Kurtis I , Arredondo, Kristen H , Abel, Taylor J , Agarwal, Nitin , Bernardo, Danilo , Crutcher, Robert , Bonda, David , Depositario‐Cabacar, Dewi, Eschbach, Krista , Gaillard, William D. , Javarayee, Pradeep , Karakas, Cemal , Novotny, Edward J. , Wolf, Steven M. , Wong‐Kisiel, Lily C.

Mayo Clinic

Epilepsia | August 3, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/epi.70379 | PMID 42545811 Get It

Abstract Objective Epilepsy duration is a modifiable risk factor in the outcome of definitive epilepsy surgery; however, an analogous effect in palliative procedures has not been shown. We reviewed the Pediatric Epilepsy Surgery Database data for an association between epilepsy duration and seizure reduction in palliative procedures. Methods Patients enrolled between January 2018 and April 2025 who underwent their first epilepsy surgery with palliative intent with 6 months of follow‐up were included. Procedures included neuromodulation, corpus callosotomy, hemispherotomy, lesionectomy, and lobectomy where surgical intent was not seizure freedom. Outcomes of seizure freedom, 90% seizure reduction, and 50% seizure reduction were considered at 6–12 months and >12 months from surgery. Duration from epilepsy onset to surgery was compared for patients above and below each outcome threshold at each time point. Logistic regression analysis for the association between epilepsy duration and seizure reduction adjusted for potential confounders including procedure type, etiology, and other clinical factors. Logistic regression analysis was performed on the overall cohort and subgroups of patients with each procedure. Results A total of 588 patients were included. Initial univariate analysis suggested that epilepsy duration at time of surgery was significantly associated with seizure freedom and 90% seizure reduction at both 6–12 months and >12 months. After adjusting for confounders, only seizure freedom at >12 months was significantly associated with duration of epilepsy. When individual procedures were considered, only lobectomy was sensitive to duration of epilepsy in multivariate analysis, with significant impacts on >50% and >90% seizure reduction at >12 months. Lesional epilepsy predicted seizure freedom at >12 months. Neuromodulation and corpus callosotomy were less likely to achieve seizure reduction than other procedures. Significance We did not find an association between early epilepsy surgery and seizure reduction. This reflects the heterogeneity of our population, including different types of surgical procedures and lesional and nonlesional epilepsies.
Continued concomitant antibiotic or immunosuppression therapies reduce the risk of pouchitis among patients with ileal pouch-anal anastomosis and primary sclerosing cholangitis
Haydek, John P. , Santiago, Priscila , Powers, Joseph Carter , Ruplall, Latchmin, Richardson, Hoang Anh, Causey, Erin, Elhawary, Mohamed, Karl, Taylor , Tfayli, Rami , Hashash, Jana G. , Qazi, Taha , Horst, Sara , Long, Millie D. , Raffals, Laura E. , Chang, Shannon , Horst, Sara , Scott, Frank I , Long, Millie D , Raffals, Laura , Barnes, Edward L , Hashash, Jana G , Haydek, John , Karl, Taylor A. , Chang, Sam S. , Scott, Frank I. , Barnes, Edward L.

Mayo Clinic

Crohn’s & Colitis 360 | August 3, 2026 | Volume: 8 | Issue: 3 | Pages: No page available

10.1093/crocol/otag091 | PMID 42598726 Get It

Abstract Background Complications such as intermittent pouchitis (IP) and chronic inflammatory disorders of the pouch (CP) are common after ileal pouch-anal anastomosis (IPAA), particularly among patients with both ulcerative colitis and primary sclerosing cholangitis (PSC). There are no standardized approaches for prophylaxis against these complications for patients with PSC undergoing IPAA. We compared outcomes among patients with PSC and IPAA who received antibiotic or immunosuppressive therapies to those who did not. Methods We designed a retrospective cohort study that included patients with ulcerative colitis and PSC from 7 tertiary care centers that underwent IPAA between 1994 and 2023. Patients were categorized on whether they received medications following IPAA that may provide primary prophylactic benefit, such as antibiotics, probiotics, immunomodulators, or biologic medications; and the proportion of patients developing IP and CP was evaluated. Results A total of 172 patients were included in the cohort, and 13 (7.6%) patients received antibiotics or immunosuppressant medications. Antibiotics and probiotics were the most common therapy (5 patients, 2.9%), followed by biologics, small-molecule inhibitors, immunomodulators, or mesalamine (all 1 patient, 0.6%). Compared to patients not receiving antibiotics or immunosuppression, patients receiving antibiotics or immunosuppression were significantly less likely to develop IP (69.2% vs 91.2%; P = .03; odds ratio 0.22; 95% CI, 0.06-0.80) and CP (23.1% vs 56.0%, P = 0.04; OR 0.24, 95% CI, 0.06-0.89). Conclusions In this retrospective cohort of patients with ulcerative colitis and PSC undergoing IPAA, usage of concomitant antibiotics or immunosuppression was low. However, use of concomitant antibiotics or immunosuppression may decrease the burden of inflammatory conditions of the pouch in these high-risk patients.
Evaluation of lung function and airway impedance in response to ultra-marathon
Joyce, Kelsey E. , Wheatley, Courtney M. , Schwartz, Jesse C., Stewart, Glenn M., Fermoyle, Caitlin C., Taylor, Bryan J., Murdock, Robert, Constantini, Keren , Robach, Paul , Gavet, Alice , Chabridon, Loïc, Bouzat, Pierre , Johnson, Bruce D. , Joyce, Kelsey E. , Stewart, Glenn M., Tiller, Nicholas B. , Fermoyle, Caitlin C. , Murdock, Robert

Mayo Clinic

Frontiers in Physiology | August 3, 2026 | Volume: 17 | Issue: No issue available | Pages: No page available

10.3389/fphys.2026.1840102 | PMID 42609269 Get It

Introduction Ultra-marathon races present a prolonged cardiopulmonary physiological stress but the magnitude, persistence, and impact of race environment on respiratory function are incompletely understood. The aim of this study is to observe the effect of ultra-marathon trail races on both lung function and airway impedance. Methods Fifty-seven individuals (49/8, M/F) participated in either the Courmayeur-Champex-Chamonix (CCC ® , 101.5km), Ultra Trail du Mont-Blanc (UMTB ® , 171.5 km), or the Hong Kong 100 (HK, 100 km) races. Participant demographics were measured pre-race and included: age (40.7±10.3 yrs); height (175.5±7.1 cm), body mass (69.7±8.3 kg). Spirometry, airway impedance (via forced oscillation technique, FOT), maximal inspiratory (MIP) and expiratory pressure (MEP), and exhaled nitric oxide (ExNO) were assessed before, immediately (18–4 hours after), and 188–24 hours post-race. Mixed effects analysis with Dunnett’s post-hoc correction were conducted to evaluate the effects of race and time. Results Results demonstrated significant effects of time for: forced vital capacity (FVC), forced expiratory flow over one second (FEV 1 ), peak expiratory flow (PEF), forced expiratory flow between 25-75% (FEF25-75), forced expiratory flow at 25% and at 50% (FEF 25 and FEF 50 , respectively), MIP, MEP, airway reactance (X) at all frequencies from FOT (X 5 , X 11 , X 19 ), respiratory rate, and ExNO (all p &lt;0.05). A significant effect of race was also observed for ExNO ( p =0.002). Discussion Findings indicate declines in lung function and airway impedance immediately after ultra-marathon races, some of which, persisted up to 24 hours post-race. Further investigations are required to better understand the etiology of changes in lung function following ultra-endurance events.
Coccidioidomycosis Testing Among Patients Hospitalized With Community-Acquired Pneumonia
Tisekar, Saima N, Saleh, Y. , Taylor, Gretchen, Blair, Janis E. , Aboalmaaty, Yehia S , Taylor, Gretchen E

Mayo Clinic

Open Forum Infectious Diseases | August 1, 2026 | Volume: 13 | Issue: 8 | Pages: No page available

10.1093/ofid/ofag499 | PMID 42592041 Get It

Abstract Among 1141 inpatients from Arizona with community-acquired pneumonia, 865 (75.8%) were tested for Coccidioides infection and 85 (9.8%) had positive results. Patients more commonly underwent testing if they had concerning radiographs, fever, dyspnea, or fatigue. Patients with night sweats, rash, headache, or eosinophilia more commonly had positive results.
Local immune networks promote respiratory IgA responses after mucosal vaccination 2260370
Wu, Yue, Xu, You, Fang, An, Zhu, Fangming , Kobayashi, Takao, Taylor, J., Hu, Hui , Kita, Hirohito, Hu, Haitao, Liu, Shan-lu, Sun, Jie, Tang, Jinyi , Chaudhuri, Arka Sen , Qu, Panke , Taylor, Justin, Kita, Hirohito , Zhang, Nu , Zhu, Guizhi

Mayo Clinic

The Journal of Immunology | July 28, 2026 | Volume: 215 | Issue: Supplement_1 | Pages: No page available

10.1093/jimmun/vkag141.911 Get It

Abstract Introduction Mucosal immunization and respiratory IgA offer significant promise in protecting against airborne pathogens, including SARS-CoV-2. However, the conditions and mechanisms that lead to the robust induction of respiratory IgA responses following mucosal vaccination remain poorly understood. Methods In this project, we established SARS-CoV-2 breakthrough infection and mucosal adenovirus-based booster vaccination models. Using genetic mouse models and various in vivo and in vitro blockade or depletion approaches, we further investigated the mechanisms regulating respiratory IgA responses. Results Here we found that a mucosal adenovirus-based booster vaccination in mouse models revealed that respiratory booster immunization elicited markedly stronger and more durable respiratory IgA, T cell response, and protective immunity against SARS-CoV-2, supporting the promise of respiratory mucosal vaccination. Mechanistically, we identified that local CD4+ T cells support respiratory IgA production by promoting IgA+ B cell class switching, proliferation, and survival in situ. This T cell help depended on interactions between local Blimp-1+ T-bet+ Th1 cells and B cells, mediated through ICOS/CD40L/MHC-II engagement and IL-21 signaling. Furthermore, lung macrophages contributed to the mucosal IgA response via TGF-β production. Consequently, mucosal administration of SARS-CoV-2 Spike-encoding mRNA encapsulated in pulmonary surfactant (PS)- incorporated lipid nanoparticles designed to target lung macrophages elicited a stronger mucosal IgA response. Conclusion Our results uncover a local cellular network supporting enhanced mucosal IgA responses, with implications for the development of optimal mucosal immunization strategies against SARS-CoV-2 and other respiratory pathogens such as H5N1 influenza. Funding Source AI147394, AG069264, AI112844, HL170961, AI154598, AI176171 to J.S., AI67986, AI177467 to Hui.H; U54CA260582 to S.L.L; R01AI168684 to G. Z.; S.L.L was also supported by a fund provided by an anonymous private donor to The Ohio State University. Topic Categories Mucosal and Regional Immunology (MUC)
Molecular and Structural Basis of Pan-Resistance to BTK Degraders and Inhibitors
Sievers, Quinlan , Lu, Hao , Cool, Allison , Gajewski, Stefan , Kong, Tim , Noviski, Mark , Whelan, Sarah , Wang, Yuhan , Navarrete, Lizbeth Mendoza, Mi, Xiaoli , Mukerji, Ratul , Ye, Jordan , Rios, Mateo Sanchez Garcia de los, Bousquet, Hugo , Tan, Y. , Brathaban, Nivetha , Narasappa, Nell , Lu, Ya‐Wen , Elechko, Jennifer, Phelps, Christopher B., Sekeres, Samantha, Bravo, Eduardo , Alencar, Alvaro J. , Islam, Prioty , Mato, Anthony R. , Noviski, Mark A , Wang, Yuhan , Mendoza Navarrete, Lizbeth , Ficici, Emel , Mukerji, Ratul , Iuliano, James N , Ye, Jordan , Sanchez Garcia De Los Rios, Mateo , Bousquet, Hugo , Tan, May , Brathaban, Nivetha , Narasappa, Nell , Lu, Ya-Wen , Elechko, Jennifer , Maron, Maxim I , Phelps, Christopher B , Rahman, Jahan , Notti, Ryan Q , Sekeres, Samantha , Lamkin, Erica N , Bravo, Eduardo , Alencar, Alvaro J , Ewalt, Mark D , Islam, Prioty , Mato, Anthony , Roeker, Lindsey , Bhatt, Shruti , Taylor, Justin , Thompson, Meghan C , Hansen, Gwenn M , Abdel-Wahab, Omar , Lamkin, Erica , Ewalt, Mark D. , Roeker, Lindsey E. , Abdel‐Wahab, Omar

Mayo Clinic

Cancer Discovery | July 22, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1158/2159-8290.cd-26-0251 | PMID 42484277 Get It

Abstract Early-phase clinical trials of Bruton’s tyrosine kinase (BTK) degraders have demonstrated efficacy in patients with BTK inhibitor-resistant chronic lymphocytic leukemia (CLL). How clinical resistance to BTK degraders arises is unknown. Here we sequenced serial CLL samples from patients enrolled in the phase I trials of zelebrudomide and bexobrutideg and observed recurrent expansion of preexisting BTK A428D mutations at relapse. Unlike previously studied BTK inhibitor resistance mutations, BTK A428D conferred pan-resistance to BTK inhibitors and degraders. In the absence of BTK-directed therapies, however, cells bearing BTK A428D exhibited a competitive disadvantage. A crystal structure of BTK A428D revealed that the mutant aspartate clashes with the adenine ring of ATP and the adenine-mimetic moiety of BTK inhibitors and degraders. Combining BTK degraders with venetoclax mitigated the expansion of BTK A428D. These results provide the molecular basis for clinical resistance to BTK degraders and will inform the development of next-generation BTK degrader therapies.
Prognostic Value of Tumor Response in Pediatric and Adult Patients With Ewing Sarcoma
Kowalchuk, Roman O. , Chihak, Melanie A., Keeney, Michael G., Fritchie, Karen , Harmsen, W.L., Weiskittel, Taylor M. , Lee, Katie N., Xu‐Welliver, Meng , Haddock, Michael G. , Allen‐Rhoades, Wendy , Schoettler, Peter J., Arndt, Carola A., Ruddy, Kathryn J. , Rose, Peter S. , Laack, Nadia N., Allen-Rhoades, Wendy A , Ahmed, Safia K. , Kowalchuk, Roman O. , Xu-Welliver, Meng , Chihak, Melanie A., Keeney, Michael, Schoettler, P.J., Arndt, Carola, Laack, Nadia N.

Mayo Clinic

Pediatric Blood & Cancer | July 21, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/1545-5017.70420 | PMID 42478587 Get It

ABSTRACT Purpose We studied histologic Ewing sarcoma (ES) tumor response at local control surgery to explore associations between histologic response and chemotherapy practice changes over time and confirm its prognostic significance in the modern era. Methods We reviewed clinical data for 126 patients with ES treated at Mayo Clinic from 1977 to 2022, analyzing the percentage necrosis as a prognostic factor across chemotherapy regimens (including modern interval‐compressed VDC‐IE). Results In the historical cohort, 5‐year event‐free survival (EFS) and overall survival (OS) for patients with ≤5% versus greater than 5% viable tumor were 76% versus 59% ( p = 0.01) and 83% versus 62% ( p = 0.01). Review of 104 specimens by two pathologists identified the percentage remaining viable tumor as more reproducible than the percentage necrosis and/or fibrosis. On multivariable analysis of patients with localized disease ( n = 87), pelvic tumors and greater than 5% viable tumor remained independent risk factors for poor survival (EFS: hazard ratio [HR] 3.1, p < 0.01; OS: HR 2.1, p = 0.048). The modern cohort consisted of 22 patients. No patients with tumor size less than 8 cm at diagnosis and 100% necrosis after surgery had events; four of seven with tumors greater than 8 cm had events despite 100% necrosis. Conclusions Our results validate the historical threshold of greater than 5% viable tumor with older chemotherapy regimens but not with modern interval‐compressed VDC‐IE. In addition, inter‐rater reliability for the percentage viable is more reproducible than the percentage necrosis. Although numbers are small, tumors less than 8 cm with no viable tumor appear to be a favorable subgroup and suggest risk stratification using a combination of tumor size and any viable tumor should be evaluated in ES.